JAK2 and myeloproliferative disorder: There has been a tremendous accumulation of information deriving by the sequencing of DNA of MPN patients, which started in 2005 with the description of a point mutation in JAK2 (V617F), marking more than 60% of all MPN, soon followed by discovery of JAK2 exon 12, MPL, and CALR mutations.